|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||113.15 - 118.00|
|52 Week Range||93.13 - 124.95|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||37.39|
|Forward Dividend & Yield||2.79 (2.36%)|
|Ex-Dividend Date||Feb. 25, 2021|
|1y Target Est||N/A|
Dr. Calvin Sun,The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on an updated guidance after Alexion acquisition.
A mixed vaccination of first AstraZeneca and then a Pfizer COVID-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed. The study involved 499 medical workers - 100 receiving mixed doses, 200 taking two doses of the Pfizer/BioNTech shot and the remainder getting two AstraZeneca shots. All showed neutralizing antibodies, which prevent the virus from entering cells and replicating, and the result of the mixed schedule of vaccines showed similar amounts of neutralizing antibodies found from the group that received two Pfizer shots.